Acting at different therapeutic levels might be another therapeutic option, since in a phase 2 trial testing cilofexor combined with the acetyl-CoA carboxylase (ACC) inhibitor firsocostat and the antidiabetic GLP-1 RAs semaglutide improved liver steatosis and liver biochemistry [302]. Here, GLP1R is linked to fatty liver disease.